Physician

Srirengam Muralidhasan, MD

According to 2025 Medicare claims, Srirengam Muralidhasan, MD (NPI: 1902898257) practices family practice in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is SRIRENGAM MURALIDHASAN MD LLC (NPI: 1215929435; TIN: 202156724) and primary practice location at 88001-6013.

Muralidhasan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 684 traditional Medicare patients, billed 6,468 HCPCS/CPT codes, and received $289,141 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 21,464 prescription claims across 1,167 beneficiaries totaling $1,971,539 in drug costs, led by Ozempic (Semaglutide). DME data shows 260 claims. Open Payments data shows 7 records totaling $133. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $980,740 to $1,971,539. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $63,974 and ending at $26,296.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	740	9,119	$289,734
2016	898	10,797	$305,991
2017	967	11,587	$320,602
2018	944	10,568	$309,951
2019	1,017	11,083	$327,455
2020	781	6,762	$248,837
2021	774	6,017	$318,609
2022	849	6,455	$322,566
2023	755	6,323	$294,291
2024	684	6,468	$289,141

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	917	20,664	$980,740
2016	993	20,916	$1,107,698
2017	986	19,659	$1,210,677
2018	1,042	20,315	$1,324,489
2019	1,123	20,175	$1,483,661
2020	1,048	20,052	$1,575,840
2021	1,033	18,409	$1,431,337
2022	1,125	19,167	$1,766,214
2023	1,124	19,661	$2,119,241
2024	1,167	21,464	$1,971,539

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	211	926	$50,364
2016	197	889	$29,745
2017	138	797	$17,432
2018	190	898	$58,051
2019	170	732	$23,418
2020	105	586	$27,439
2021	47	413	$32,902
2022	82	476	$30,844
2023	63	471	$34,873
2024	51	260	$15,862

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	318	318	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	426	1,293	$83
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	453	1,040	$56
87426	Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus	189	252	$33
G0444	Annual depression screening, 5 to 15 minutes	225	225	$17

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	270	9,220	$285,733
Jardiance	Empagliflozin	287	15,079	$283,712
Eliquis	Apixaban	179	10,172	$194,549
Farxiga	Dapagliflozin Propanediol	136	6,655	$117,365
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	115	4,050	$84,994

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	17	$8,609
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	11	81	$5,155
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	28	71	$923
E1392	Portable oxygen concentrator, rental	Y	N/R	19	$581
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	35	$502

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$133	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Srirengam Muralidhasan, MD?

Tedicare shows public-source Medicare data for Srirengam Muralidhasan, MD (NPI 1902898257), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Srirengam Muralidhasan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Srirengam Muralidhasan, MD?

Srirengam Muralidhasan, MD is linked to SRIRENGAM MURALIDHASAN MD LLC (billing NPI 1215929435) in the available physician profile data.

Does Srirengam Muralidhasan, MD have Open Payments data?

Srirengam Muralidhasan, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.